Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-09-16
2000-03-07
Martinell, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 235, A61K 4736
Patent
active
060340711
ABSTRACT:
The present invention relates to therapeutic uses of mutant activated G.sub.s .alpha. and adenylyl cyclase 2. Although mutant activated G.sub.s .alpha. has been, previously, associated with proliferative and physiological disorders of a subset of differentiated cells, it has now been discovered that mutant activated G.sub.s .alpha. (referred to, hereafter, as G.sub.s .alpha.*) can suppress proliferation as well as the transformed phenotype. Accordingly, in various embodiments of the present invention, introduction of G.sub.s .alpha.* into cells or tissues, preferably by the use of viral vectors, may be used to reduce proliferation and/or prevent the development, reduce, or reverse malignancy. In further embodiments of the present invention, the introduction of adenylyl cyclase 2, preferably using viral vectors, may be used to limit cell proliferation and/or reduce the transformed phenotype. Because adenylyl cyclase 2 is not endogenous to most tissues but can be activated in a subset of malignant or otherwise proliferative cells (e.g., those in which growth factors stimulate phospholipases C and/or D), the introduction of adenylyl cyclase 2 may be used to selectively increase cAMP levels and thereby prevent, reduce, or reverse proliferation and/or malignancy and thus relieve the pathophysiological state.
REFERENCES:
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Orkin et al (Co-Chairs), Dec. 7, 1995.
Premont et al., Meth. Enzymol. 238:116-127, 1994.
Cowley et al., Cell 77:841-852, 1994.
Chen et al., Science 263:1278-1281, 1994.
Iyengar, R., FASEB J. 7:768-775, 1993.
Pieroni et al., Curr. Opin. Neurobiol. 3:345-351, 1993.
Jacobowitz et al., J. Biol. Chem. 268:3829-3832, 1993.
Yoshimura et la., J. Biol. Chem. 268:4604-4607, 1993.
Marx Science 260:1588-1590, 1993.
Taussig et al., J. Biol. Chem. 268:9-12, 1993.
Graves et al., Proc. Natl. Acad. Sci. USA 90:10300-10304, 1993.
Assender et al., Biochem. J. 288:527-532, 1992.
Stengel et al., Hum. Genet. 90:126-130, 1992.
Federman et al., Nature 356:159-161, 1992.
DeVivo et al., J. Biol. Chem. 267:18263-18266, 1992.
Levine, M., N. Engl. J. Med. 325:1738-1740, 1991.
Weinstein et al., N. Engl. J. Med. 325:1688-1695, 1991.
Feinstein et al., Proc. Natl. Acad. Sci. USA 88:10173-10177, 1991.
Bourne et al., Nature 349:117, 1991.
Landis et al., Nature 340:692-696, 1989.
van Corven et al., Cell 59:45-54, 1989.
Gilman, A., Ann. Rev. Biochem. 56:615-649, 1987.
Clegg et al., J. Biol. Chem. 262:13111-13119, 1987.
Dickson et al., Science 232:1540-1543, 1986.
Mattera et al., FEBS 206:36-42, 1986.
Harris et al., Science 229:1274-1277, 1985.
Clark Richard S.
Martinell James
LandOfFree
Mutant activated G.sub.S .alpha. and adenylyl cyclase 2 for use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant activated G.sub.S .alpha. and adenylyl cyclase 2 for use , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant activated G.sub.S .alpha. and adenylyl cyclase 2 for use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-363225